Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer is a research paper published in JTO Clinical and Research Reports (2020). On theSindex it has a DataRank of 0.470. It has been cited 22 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: R01 CA169259
National Cancer Institute
Grant: R01 CA240257
National Cancer Institute
Grant: R37 CA218707
U.S. Department of Defense
Grant: LC170223
National Institutes of Health
Grant: 5R01CA169259-02
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
National Institutes of Health
Grant: 5R01CA240257-02
Role of KAT5 in lung cancer
National Institutes of Health
Grant: 5R37CA218707-07
Unmet needs for specific subsets of EGFR mutated lung cancer
National Cancer Institute
U.S. Department of Defense
FWCI
1.43
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
Additional file 1 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
Additional file 2 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
Additional file 2 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation